Literature DB >> 19288219

Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.

Ercument Cengiz1, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Mustafa K Gul, Cigdem Erten, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A Sanli, Ruchan Uslu.   

Abstract

Drug resistance is a significant challenge of daily oncology practice. Docetaxel and gossypol both have antitumoral activity in hormone-refractory prostate cancer (HRPC). Our results revealed that docetaxel and gossypol were synergistically cytotoxic and apoptotic in PC-3 cells in a dose- and time-dependent manner. We further investigated the expression profiles of genes involved in drug resistance and metabolism with a Human Cancer Drug Resistance and Metabolism PCR Array (SuperArray). Six of the 84 genes that are known to regulate drug resistance, metabolism, cell cycle, DNA repair and oncogenesis were downregulated >or=3-fold change by the combination treatment. These results may be important in devising mechanism-based and targeted therapeutic strategies for prostate cancer, especially in devising combination therapy for drug resistant prostate cancers.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19288219     DOI： 10.1007/s11033-009-9501-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN： 0301-4851            Impact factor:   2.316


  31 in total

1.  Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray.

Authors:  Yiwei Li; Xingli Li; Maha Hussain; Fazlul H Sarkar
Journal:  Neoplasia       Date:  2004 Mar-Apr       Impact factor: 5.715

2.  Her-2-neu expression and progression toward androgen independence in human prostate cancer.

Authors:  S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

3.  Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial.

Authors:  G Hudes; L Einhorn; E Ross; A Balsham; P Loehrer; H Ramsey; J Sprandio; M Entmacher; W Dugan; R Ansari; F Monaco; M Hanna; B Roth
Journal:  J Clin Oncol       Date:  1999-10       Impact factor: 44.544

Review 4.  Minireview: Cyclin D1: normal and abnormal functions.

Authors:  Maofu Fu; Chenguang Wang; Zhiping Li; Toshiyuki Sakamaki; Richard G Pestell
Journal:  Endocrinology       Date:  2004-08-26       Impact factor: 4.736

5.  The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.

Authors:  W Ki Hong
Journal:  Oncology (Williston Park)       Date:  2002-06       Impact factor: 2.990

Review 6.  Drug methylation in cancer therapy: lessons from the TPMT polymorphism.

Authors:  Eugene Krynetski; William E Evans
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 7.  Docetaxel (taxotere) in the treatment of prostate cancer.

Authors:  Tomasz M Beer; Mohammed El-Geneidi; Kristine M Eilers
Journal:  Expert Rev Anticancer Ther       Date:  2003-06       Impact factor: 4.512

8.  Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance.

Authors:  B W Futscher; N E Foley; M C Gleason-Guzman; P S Meltzer; D M Sullivan; W S Dalton
Journal:  Int J Cancer       Date:  1996-05-16       Impact factor: 7.396

9.  Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells.

Authors:  C Friesen; I Herr; P H Krammer; K M Debatin
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence.

Authors:  E Hernes; S D Fosså; Aa Berner; B Otnes; J M Nesland
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640
View more
  15 in total

1.  Design, synthesis, and ex vivo evaluation of a selective inhibitor for retinaldehyde dehydrogenase enzymes.

Authors:  Angelica R Harper; Anh T Le; Timothy Mather; Anthony Burgett; William Berry; Jody A Summers
Journal:  Bioorg Med Chem       Date:  2018-10-24       Impact factor: 3.641

2.  Regulation of apoptosis-related molecules by synergistic combination of all-trans retinoic acid and zoledronic acid in hormone-refractory prostate cancer cell lines.

Authors:  Bulent Karabulut; Burcak Karaca; Harika Atmaca; Asli Kisim; Selim Uzunoglu; Canfeza Sezgin; Ruchan Uslu
Journal:  Mol Biol Rep       Date:  2010-03-28       Impact factor: 2.316

3.  Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells.

Authors:  Kai Wang; Linfeng Cheng; Yinghong Liang; Donghui Liu; Kai Li; Ping Wang
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

4.  Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer.

Authors:  Thomas K Hamilton; Nianping Hu; Klodiana Kolomitro; Erin N Bell; Donald H Maurice; Charles H Graham; D Robert Siemens
Journal:  World J Urol       Date:  2012-03-02       Impact factor: 4.226

5.  PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.

Authors:  Prashanth K B Nagesh; Nia R Johnson; Vijaya K N Boya; Pallabita Chowdhury; Shadi F Othman; Vahid Khalilzad-Sharghi; Bilal B Hafeez; Aditya Ganju; Sheema Khan; Stephen W Behrman; Nadeem Zafar; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu
Journal:  Colloids Surf B Biointerfaces       Date:  2016-03-26       Impact factor: 5.268

6.  Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects.

Authors:  Atsushi Imai; Benjamin D Zeitlin; Fernanda Visioli; Zhihong Dong; Zhaocheng Zhang; Sudha Krishnamurthy; Emily Light; Frank Worden; Shaomeng Wang; Jacques E Nör
Journal:  Cancer Res       Date:  2011-12-08       Impact factor: 12.701

Review 7.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

8.  Co-delivery with nano-quercetin enhances doxorubicin-mediated cytotoxicity against MCF-7 cells.

Authors:  Akbar Minaei; Mehdi Sabzichi; Fatemeh Ramezani; Hamed Hamishehkar; Nasser Samadi
Journal:  Mol Biol Rep       Date:  2016-01-09       Impact factor: 2.316

9.  Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.

Authors:  Burcak Karaca; Harika Atmaca; Emir Bozkurt; Asli Kisim; Selim Uzunoglu; Bülent Karabulut; Canfeza Sezgin; Ulus Ali Sanli; Ruchan Uslu
Journal:  Mol Biol Rep       Date:  2012-12-27       Impact factor: 2.316

10.  Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.

Authors:  Foong Ying Wong; Natalia Liem; Chen Xie; Fui Leng Yan; Wing Cheong Wong; Lingzhi Wang; Wei-Peng Yong
Journal:  PLoS One       Date:  2012-12-04       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.